Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2022.102338
Abstract: BACKGROUND In pancreatic ductal adenocarcinoma cytoreduction can be curative, or palliative. FOLFIRINOX and GEM-NAB are the two FDA/EMA approved regimens for advanced disease. We aim to identified the most cytoreductive regimen on the basis of… read more here.
Keywords: meta analysis; gem nab; cytoreduction;
Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01)
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Surgery"
DOI: 10.1097/sla.0000000000005430
Abstract: Objective: Given the frequent adverse events with multidrug chemotherapy, not only the survival benefit but also the feasibility of using neoadjuvant chemotherapy to treat pancreatic cancer need to be clarified. Summary of Background Data: Although… read more here.
Keywords: neoadjuvant chemotherapy; pancreatic cancer; gem nab; chemotherapy ... See more keywords
Comparative Safety and Efficacy of Therapeutic Options in Resectable and Advanced/Metastatic Pancreatic Cancer: A Systematic Review and Indirect Comparison
Sign Up to like & getrecommendations! Published in 2021 at "Oncology Research and Treatment"
DOI: 10.1159/000517409
Abstract: Objectives: FOLFIRINOX, gemcitabine/nab-paclitaxel (gem-nab/P), and gemcitabine-capecitabine (gem-cap) demonstrated superiority over gemcitabine monotherapy for pancreatic cancer (PC). It is still unclear which chemotherapy regimen is the most optimal. This study aimed to conduct a systematic review… read more here.
Keywords: gem; gem nab; resectable advanced; gem cap ... See more keywords
Predictive value of plasma tumor mutation burden (TMB) in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs. GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.3_suppl.411
Abstract: 411Background: PA.7 evaluated whether combining PD-L1 and CTLA-4 inhibition with GEM and Nab-P increases efficacy as first line therapy in mPDAC. High TMB is associated with immunotherapy sensitivi... read more here.
Keywords: line therapy; gem nab; gem; first line ... See more keywords